276 related articles for article (PubMed ID: 28505196)
1. Unveiling a novel transient druggable pocket in BACE-1 through molecular simulations: Conformational analysis and binding mode of multisite inhibitors.
Di Pietro O; Juárez-Jiménez J; Muñoz-Torrero D; Laughton CA; Luque FJ
PLoS One; 2017; 12(5):e0177683. PubMed ID: 28505196
[TBL] [Abstract][Full Text] [Related]
2. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.
Kumar A; Srivastava G; Negi AS; Sharma A
J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523
[TBL] [Abstract][Full Text] [Related]
3. Study on the active mechanism of β-secretase inhibitors by molecular simulations.
Tian YL; Lv M; Li JJ; Xu T; Zhai HL; Zhang XY
Eur J Pharm Sci; 2015 Aug; 76():138-48. PubMed ID: 25965961
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridines as small molecule BACE-1 inhibitors.
Razzaghi-Asl N; Firuzi O; Hemmateenejad B; Javidnia K; Edraki N; Miri R
Bioorg Med Chem; 2013 Nov; 21(22):6893-909. PubMed ID: 24113238
[TBL] [Abstract][Full Text] [Related]
5. Conformational Dynamics and Binding Free Energies of Inhibitors of BACE-1: From the Perspective of Protonation Equilibria.
Kim MO; Blachly PG; McCammon JA
PLoS Comput Biol; 2015 Oct; 11(10):e1004341. PubMed ID: 26506513
[TBL] [Abstract][Full Text] [Related]
6. Dynamic Docking of a Medium-Sized Molecule to Its Receptor by Multicanonical MD Simulations.
Bekker GJ; Araki M; Oshima K; Okuno Y; Kamiya N
J Phys Chem B; 2019 Mar; 123(11):2479-2490. PubMed ID: 30808168
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of 1,4-dihydropyridine derivatives as BACE-1 inhibitors.
Choi SJ; Cho JH; Im I; Lee SD; Jang JY; Oh YM; Jung YK; Jeon ES; Kim YC
Eur J Med Chem; 2010 Jun; 45(6):2578-90. PubMed ID: 20303626
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of an Allosteric BACE Inhibitor Peptide to Identify Mimetics that Can Interact with the Loop F Region of the Enzyme and Prevent APP Cleavage.
Campagna J; Vadivel K; Jagodzinska B; Jun M; Bilousova T; Spilman P; John V
J Mol Biol; 2018 May; 430(11):1566-1576. PubMed ID: 29649434
[TBL] [Abstract][Full Text] [Related]
9. Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme β-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer`s disease.
Silva-Junior EF; Barcellos Franca PH; Quintans-Junior LJ; Mendonca-Junior FJB; Scotti L; Scotti MT; de Aquino TM; de Araujo-Junior JX
Curr Comput Aided Drug Des; 2017 Nov; 13(4):266-274. PubMed ID: 28382866
[TBL] [Abstract][Full Text] [Related]
10. Retrospective molecular docking study of WY-25105 ligand to β-secretase and bias of the three-dimensional structure flexibility.
Ghemtio L; Muzet N
J Mol Model; 2013 Aug; 19(8):2971-9. PubMed ID: 23564327
[TBL] [Abstract][Full Text] [Related]
11. Investigation of naphthofuran moiety as potential dual inhibitor against BACE-1 and GSK-3β: molecular dynamics simulations, binding energy, and network analysis to identify first-in-class dual inhibitors against Alzheimer's disease.
Kumar A; Srivastava G; Srivastava S; Verma S; Negi AS; Sharma A
J Mol Model; 2017 Aug; 23(8):239. PubMed ID: 28741112
[TBL] [Abstract][Full Text] [Related]
12. Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies.
John S; Thangapandian S; Sakkiah S; Lee KW
BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S28. PubMed ID: 21342558
[TBL] [Abstract][Full Text] [Related]
13. Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors.
Veenstra SJ; Rueeger H; Voegtle M; Lueoend R; Holzer P; Hurth K; Tintelnot-Blomley M; Frederiksen M; Rondeau JM; Jacobson L; Staufenbiel M; Neumann U; Machauer R
Bioorg Med Chem Lett; 2018 Jul; 28(12):2195-2200. PubMed ID: 29764741
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive 3D-QSAR and binding mode of BACE-1 inhibitors using R-group search and molecular docking.
Huang D; Liu Y; Shi B; Li Y; Wang G; Liang G
J Mol Graph Model; 2013 Sep; 45():65-83. PubMed ID: 24004830
[TBL] [Abstract][Full Text] [Related]
15. A PM7 dynamic residue-ligand interactions energy landscape of the BACE1 inhibitory pathway by hydroxyethylamine compounds. Part I: The flap closure process.
Gueto-Tettay C; Martinez-Consuegra A; Zuchniarz J; Gueto-Tettay LR; Drosos-Ramírez JC
J Mol Graph Model; 2017 Sep; 76():274-288. PubMed ID: 28746905
[TBL] [Abstract][Full Text] [Related]
16. Deep neural network affinity model for BACE inhibitors in D3R Grand Challenge 4.
Wang B; Ng HL
J Comput Aided Mol Des; 2020 Feb; 34(2):201-217. PubMed ID: 31916049
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of donepezil analogues as dual AChE and BACE-1 inhibitors.
Gabr MT; Abdel-Raziq MS
Bioorg Chem; 2018 Oct; 80():245-252. PubMed ID: 29966870
[TBL] [Abstract][Full Text] [Related]
18. Tyramine fragment binding to BACE-1.
Kuglstatter A; Stahl M; Peters JU; Huber W; Stihle M; Schlatter D; Benz J; Ruf A; Roth D; Enderle T; Hennig M
Bioorg Med Chem Lett; 2008 Feb; 18(4):1304-7. PubMed ID: 18226904
[TBL] [Abstract][Full Text] [Related]
19. The potential of natural product vs neurodegenerative disorders: In silico study of artoflavanocoumarin as BACE-1 inhibitor.
Razzaghi-Asl N; Karimi A; Ebadi A
Comput Biol Chem; 2018 Dec; 77():307-317. PubMed ID: 30445338
[TBL] [Abstract][Full Text] [Related]
20. D3R Grand Challenge 4: ligand similarity and MM-GBSA-based pose prediction and affinity ranking for BACE-1 inhibitors.
Sasmal S; El Khoury L; Mobley DL
J Comput Aided Mol Des; 2020 Feb; 34(2):163-177. PubMed ID: 31781990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
